DOCSLIB.ORG

Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Anatomical Therapeutic Chemical Equivalent Generic Product Name Product Description Number (DIN) (ATC) Drug Classification HALOPERIDOL INJECTION 17574 HALDOL INJECTION 5MG/ML N05AD01 HALOPERIDOL TRIFLUOPERAZINE HCL 21865 NOVO-FLURAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21873 NOVO-FLURAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21881 NOVO-FLURAZINE TAB 10MG N05AB06 TRIFLUOPERAZINE THIORIDAZINE 27375 MELLARIL SUS 10MG/5ML N05AC02 THIORIDAZINE FLUPHENAZINE ENANTHATE 29173 MODITEN ENANTHATE INJ 25MG/ML N05AB02 FLUPHENAZINE THIORIDAZINE HYDROCHLORIDE 37486 NOVO-RIDAZINE 50MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37494 NOVO-RIDAZINE 25MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37508 NOVO-RIDAZINE 10MG N05AC02 THIORIDAZINE CHLORPROMAZINE HCL 232157 NOVO-CHLORPROMAZINE TAB 10MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232807 NOVO-CHLORPROMAZINE TAB 50MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232823 NOVO-CHLORPROMAZINE TAB 25MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232831 NOVO-CHLORPROMAZINE TAB 100MG N05AA01 CHLORPROMAZINE LITHIUM CARBONATE 236683 CARBOLITH CAP 300MG N05AN01 LITHIUM TRIFLUOPERAZINE HCL 312746 APO TRIFLUOPERAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 312754 APO TRIFLUOPERAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE PIMOZIDE 313815 ORAP TAB 2MG N05AG02 PIMOZIDE PIMOZIDE 313823 ORAP TAB 4MG N05AG02 PIMOZIDE TRIFLUOPERAZINE HCL 326836 APO TRIFLUOPERAZINE TAB 10MG N05AB06 TRIFLUOPERAZINE PERPHENAZINE 335118 APO PERPHENAZINE TAB 8MG N05AB03 PERPHENAZINE PERPHENAZINE 335126 APO PERPHENAZINE TAB 4MG N05AB03 PERPHENAZINE PERPHENAZINE 335134 APO PERPHENAZINE TAB 2MG N05AB03 PERPHENAZINE TRIFLUOPERAZINE HCL 345539 APO TRIFLUOPERAZINE TAB 1MG N05AB06 TRIFLUOPERAZINE FLUPHENAZINE DECANOATE 349917 MODECATE INJ 25MG/ML N05AB02 FLUPHENAZINE THIORIDAZINE HYDROCHLORIDE 360198 APO THIORIDAZINE TAB 25MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 360228 APO THIORIDAZINE TAB 10MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 360236 APO THIORIDAZINE TAB 50MG N05AC02 THIORIDAZINE HALOPERIDOL 363650 NOVO-PERIDOL TAB 5MG N05AD01 HALOPERIDOL HALOPERIDOL 363669 NOVO-PERIDOL TAB 2MG N05AD01 HALOPERIDOL HALOPERIDOL 363677 NOVO-PERIDOL TAB 1MG N05AD01 HALOPERIDOL HALOPERIDOL 363685 NOVO-PERIDOL TAB 0.5MG N05AD01 HALOPERIDOL HALOPERIDOL 396796 APO HALOPERIDOL TAB 0.5MG N05AD01 HALOPERIDOL HALOPERIDOL 396818 APO HALOPERIDOL TAB 1MG N05AD01 HALOPERIDOL HALOPERIDOL 396826 APO-HALOPERIDOL TAB 2MG N05AD01 HALOPERIDOL HALOPERIDOL 396834 APO-HALOPERIDOL TAB 5MG N05AD01 HALOPERIDOL LITHIUM CARBONATE 461733 CARBOLITH CAP 150MG N05AN01 LITHIUM HALOPERIDOL 552429 PERIDOL N05AD01 HALOPERIDOL CHLORPROMAZINE HCL 580988 CHLORPROMANYL 20 SYR N05AA01 CHLORPROMAZINE FLUPENTHIXOL HCL 585157 FLUANXOL TAB 3MG N05AF01 FLUPENTIXOL HALOPERIDOL 587702 APO HALOPERIDOL LIQ 2MG/ML N05AD01 HALOPERIDOL LITHIUM CARBONATE 590665 DURALITH TAB 300MG N05AN01 LITHIUM PROCHLORPERAZINE MALEATE 753637 PMS-PROCHLORPERAZINE TAB 10MG N05AB04 PROCHLORPERAZINE PROCHLORPERAZINE MALEATE 753661 PMS-PROCHLORPERAZINE TAB 5MG N05AB04 PROCHLORPERAZINE PROCHLORPERAZINE 753688 PMS-PROCHLORPERAZINE SUPPOSITO N05AB04 PROCHLORPERAZINE HALOPERIDOL 759503 PMS-HALOPERIDOL SOLN 2MG/ML N05AD01 HALOPERIDOL THIORIDAZINE HYDROCHLORIDE 775320 PMS-THIORIDAZINE SOLUTION 30MG N05AC02 THIORIDAZINE PROCHLORPERAZINE 789720 PROCHLORPERAZINE SUPPOSITOIRE N05AB04 PROCHLORPERAZINE PROCHLORPERAZINE 886432 APO-PROCHLORAZINE N05AB04 PROCHLORPERAZINE PROCHLORPERAZINE MALEATE 886440 APO-PROCHLORPERAZINE N05AB04 PROCHLORPERAZINE CLOZAPINE 894737 CLOZARIL TAB 25MG N05AH02 CLOZAPINE CLOZAPINE 894745 CLOZARIL TAB 100MG N05AH02 CLOZAPINE HALOPERIDOL DECANOATE 5ML 980781 HALDOL-LA 5ML PERICYAZINE 1926780 NEULEPTIL 5 CAP 5MG N05AC01 PERICIAZINE METHOTRIMEPRAZINE 1927647 NOZINAN TAB 2MG N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 1927655 NOZINAN TAB 5MG N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 1927663 NOZINAN TAB 25MG N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 1927671 NOZINAN TAB 50MG N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE HCL 1927698 NOZINAN INJ 25MG/ML N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 1927728 NOZINAN LIQ 5MG/ML N05AA02 LEVOMEPROMAZINE PROCHLORPERAZINE 1927752 STEMETIL TAB 5MG N05AB04 PROCHLORPERAZINE PROCHLORPERAZINE 1927760 STEMETIL TAB 10MG N05AB04 PROCHLORPERAZINE CHLORPROMAZINE 1929968 LARGACTIL LIQ 25MG/5ML N05AA01 CHLORPROMAZINE CHLORPROMAZINE 1929976 LARGACTIL LIQ 100MG/5ML N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 1929984 LARGACTIL INJ 50MG/AMP N05AA01 CHLORPROMAZINE Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Anatomical Therapeutic Chemical Equivalent Generic Product Name Product Description Number (DIN) (ATC) Drug Classification PROCHLORPERAZINE 1964399 NU PROCHLOR TAB 5MG N05AB04 PROCHLORPERAZINE METHOTRIMEPRAZINE 5MG TAB 1964909 NOVO-MEPRAZINE 5MG TAB N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 25MG TAB 1964925 NOVO-MEPRAZINE 25MG TAB N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 50MG TAB 1964933 NOVO-MEPRAZINE 50MG TAB N05AA02 LEVOMEPROMAZINE RISPERIDONE 2025280 RISPERDAL TAB 1MG N05AX08 RISPERIDONE RISPERIDONE 2025299 RISPERDAL TAB 2MG N05AX08 RISPERIDONE RISPERIDONE 2025302 RISPERDAL 3MG TAB N05AX08 RISPERIDONE RISPERIDONE 2025310 RISPERDAL 4MG TAB N05AX08 RISPERIDONE LITHIUM ION 2074834 PMS-LITHIUM CITRATE SYR 8MMO/5 N05AN01 LITHIUM HALOPERIDOL DECANOATE 2130297 HALOPERIDOL LA INJ 50MG/ML N05AD01 HALOPERIDOL HALOPERIDOL DECANOATE 2130300 HALOPERIDOL LA INJ 100MG/ML N05AD01 HALOPERIDOL FLUPENTHIXOL HCL 2156008 FLUANXOL TAB 0.5MG N05AF01 FLUPENTIXOL FLUPENTHIXOL HCL 2156016 FLUANXOL 3MG TAB N05AF01 FLUPENTIXOL FLUPENTHIXOL DECANOATE 2156032 FLUANXOL DEPOT INJ 20MG/ML N05AF01 FLUPENTIXOL FLUPENTHIXOL DECANOATE 2156040 FLUANXOL DEPOT INJ 100MG/ML N05AF01 FLUPENTIXOL ZUCLOPENTHIXOL DHCL 10MG TAB 2162903 CLOPIXOL 10MG TAB N05AF05 ZUCLOPENTHIXOL TETRABENZINE 2199270 NITOMAN TAB 25MG N05AK01 TETRABENAZINE LITHIUM CARBONATE 150MG 2216132 PMS-LITHIUM CARBONATE CAP150MG N05AN01 LITHIUM LITHIUM CARBONATE 300MG 2216140 PMS-LITHIUM CARBONATE CAP300MG N05AN01 LITHIUM LITHIUM CARBONATE 2216159 PMS-LITHIUM CARBONATE N05AN01 LITHIUM OLANZAPINE 2229250 ZYPREXA N05AH03 OLANZAPINE OLANZAPINE 2229269 ZYPREXA TAB 5MG N05AH03 OLANZAPINE OLANZAPINE 2229277 ZYPREXA TAB 7.5MG N05AH03 OLANZAPINE OLANZAPINE 2229285 ZYPREXA TAB 10MG N05AH03 OLANZAPINE THIORIDAZINE 2229553 NOVO-RIDAZINE N05AC02 THIORIDAZINE ZUCLOPENTHIXOL DHCL 10MG TAB 2230402 CLOPIXOL 10MG TAB N05AF05 ZUCLOPENTHIXOL ZUCLOPENTHIXOL DHCL 25MG TAB 2230403 CLOPIXOL 25MG TAB N05AF05 ZUCLOPENTHIXOL ZUCLOPENTHIXOL DECANOATE INJ 2230406 CLOPIXOL DECANOATE 200MG/ML N05AF05 ZUCLOPENTHIXOL LOXAPINE SUCCINATE 2230837 PMS-LOXAPINE N05AH01 LOXAPINE LOXAPINE SUCCINATE 2230838 PMS-LOXAPINE N05AH01 LOXAPINE METHOTRIMEPRAZINE 2232903 PMS-METHOTRIMEPRAZINE N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 2232904 PMS-METHOTRIMEPRAZINE N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 2232905 PMS-METHOTRIMEPRAZINE N05AA02 LEVOMEPROMAZINE RISPERIDONE 2236950 RISPERDAL N05AX08 RISPERIDONE LOXAPINE SUCCINATE 2237651 APO-LOXAPINE N05AH01 LOXAPINE LOXAPINE SUCCINATE 2237652 APO-LOXAPINE N05AH01 LOXAPINE METHOTRIMEPRAZINE 2238403 APO-METHOPRAZINE N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 2238404 APO-METHOPRAZINE N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 2238405 APO-METHOPRAZINE N05AA02 LEVOMEPROMAZINE METHOTRIMEPRAZINE 2238406 APO-METHOPRAZINE N05AA02 LEVOMEPROMAZINE OLANZAPINE 2238850 ZYPREXA N05AH03 OLANZAPINE RISPERIDONE 2240551 RISPERDAL N05AX08 RISPERIDONE RISPERIDONE 2240552 RISPERDAL N05AX08 RISPERIDONE HALOPERIDOL DECANATE 2242362 APO-HALOPERIDOL LA N05AD01 HALOPERIDOL LITHIUM CARBONATE 2242837 APO-LITHIUM CARBONATE N05AN01 LITHIUM LITHIUM CARBONATE 2242838 APO-LITHIUM CARBONATE N05AN01 LITHIUM OLANZAPINE 2243086 ZYPREXA ZYDIS N05AH03 OLANZAPINE OLANZAPINE 2243087 ZYPREXA ZYDIS N05AH03 OLANZAPINE OLANZAPINE 2243088 ZYPREXA-ZYDIS N05AH03 OLANZAPINE FLUPHENAZINE DECANOATE 2244166 APO-FLUPHENAZINE N05AB02 FLUPHENAZINE PIMOZIDE 2245432 APO-PIMOZIDE N05AG02 PIMOZIDE PIMOZIDE 2245433 APO-PIMOZIDE N05AG02 PIMOZIDE CLOZAPINE 2247243 GEN-CLOZAPINE N05AH02 CLOZAPINE CLOZAPINE 2247244 GEN-CLOZAPINE N05AH02 CLOZAPINE RISPERIDONE 2247704 RISPERDAL M N05AX08 RISPERIDONE RISPERIDONE 2247705 RISPERDAL M N05AX08 RISPERIDONE RISPERIDONE 2247706 RISPERDAL M N05AX08 RISPERIDONE RISPERIDONE 2255707 RISPERDAL CONSTA N05AX08 RISPERIDONE RISPERIDONE 2255758 RISPERDAL CONSTA N05AX08 RISPERIDONE LITHIUM CARBONATE 2266695 APO-LITHIUM CARBONATE N05AN01 LITHIUM Source: Brownell M, De Coster C, Penfold R, Derksen S, Au W, Schultz J, Dahl M. Manitoba Child Health Atlas Update Winnipeg, MB: Manitoba Centre for Health Policy, 2008.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
  • Antipsychotics and the Risk of Sudden Cardiac Death

    Antipsychotics and the Risk of Sudden Cardiac Death

    ORIGINAL INVESTIGATION Antipsychotics and the Risk of Sudden Cardiac Death Sabine M. J. M. Straus, MD; Gyse`le S. Bleumink, MD; Jeanne P. Dieleman, PhD; Johan van der Lei, MD, PhD; Geert W. ‘t Jong, PhD; J. Herre Kingma, MD, PhD; Miriam C. J. M. Sturkenboom, PhD; Bruno H. C. Stricker, PhD Background: Antipsychotics have been associated with Results: The study population comprised 554 cases of prolongation of the corrected QT interval and sudden car- sudden cardiac death. Current use of antipsychotics was diac death. Only a few epidemiological studies have in- associated with a 3-fold increase in risk of sudden car- vestigated this association. We performed a case- diac death. The risk of sudden cardiac death was high- control study to investigate the association between use est among those using butyrophenone antipsychotics, of antipsychotics and sudden cardiac death in a well- those with a defined daily dose equivalent of more than defined community-dwelling population. 0.5 and short-term (Յ90 days) users. The association with current antipsychotic use was higher for witnessed cases Methods: We performed a population-based case-control (n=334) than for unwitnessed cases. study in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with com- Conclusions: Current use of antipsychotics in a gen- plete medical records from 150 general practitioners. All eral population is associated with an increased risk of sud- instances of death between January 1, 1995, and April 1, den cardiac death, even at a low dose and for indica- 2001, were reviewed. Sudden cardiac death was classified tions other than schizophrenia.
  • Importance of the Newer Generations Of

    Importance of the Newer Generations Of

    Psychiatria Danubina, 2013; Vol. 25, No. 3, pp 329-333 Conference paper © Medicinska naklada - Zagreb, Croatia IMPORTANCE OF THE NEWER GENERATIONS OF ANTIPSYCHOTICS IN REDUCING SCHIZOPHRENIA HOSPITALIZATION RATES Vlado Jukić, Aleksandar Savić & Miroslav Herceg University Psychiatric Hospital Vrapče, Zagreb, Croatia SUMMARY Throughout history, given the lack of understanding of schizophrenia and lack of effective treatment options, patients were often committed to asylums and later psychiatric institutions, often for prolonged periods of time. First antipsychotic medications helped to bring about changes in approach to these patients and facilitated deinstitutionalization, and discovery of new drugs with differing side-effects profiles introduced new options in treating schizophrenia patients. Data on hospitalization of patients in University Psychiatric Hospital Vrapče from the mid-1990s, as well as data on national level, suggests a trend of drop in hospitalization of schizophrenia patients. At the same time, that period saw significant increase in a number of available newer-generations antipsychotics and the rise in their use compared to first-generation one. Although far from being the only contributing factor, seem to play an important role in continuing the trend of reducing hospitalization rates for schizophrenia patients that started with first antipsychotics. Newer antipsychotics with a more tolerable side-effects profile promote better compliance and further reduce rate of relapse and hospitalizations. No less important is the contribution of newer antipsychotics with new receptor profiles to the personalized psychopharmacotherapy approach that is in tune with emerging conceptualizations of schizophrenia as a complex syndrome with a number of separate symptom domains, whose specific combinations produce specific individual clinical presentation and in turn ask for a specific individual approach to the patient.
  • Ecstasy and the Concomitant Use of Pharmaceuticals

    Ecstasy and the Concomitant Use of Pharmaceuticals

    J.Copeland, P. Dillon & M. Gascoigne Ecstasy and the Concomitant Use of Pharmaceuticals NDARC Technical Report No. 201 ECSTASY AND THE CONCOMITANT USE OF PHARMACEUTICALS Jan Copeland (PhD), Paul Dillon & Michael Gascoigne Technical Report Number 201 ISBN: 1 877027 92 8 ©National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 2004 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 2 ACKNOWLEDGEMENT This study and report was funded by the Australian Government Department of Health and Ageing’s National Illicit Drug Strategy. It was conducted concurrently with a study of aspects of information seeking among ecstasy users and there is some replication of the data presented on demographic characteristics and perception of ecstasy related harms in this Technical Report and Technical Report Number 202. 3 TABLE OF CONTENTS ACKNOWLEDGEMENT 3 TABLE OF CONTENTS 4 TABLE OF TABLES 5 EXECUTIVE SUMMARY 6 INTRODUCTION 7 Anti-depressant medication 8 5-hydroxytryptophan 9 Attention Deficit Hyperactivity Disorder 11 Sildenafil Citrate 12 Benzodiazepines 13 Study Ains 14 METHOD 15 Participants 15 Procedure 15 Measures 15 RESULTS 17 Demographics
  • Drug Screening: Actual Status, Pitfalls and Suggestions for Improvement Drogenscreening: Gegenwa¨ Rtiger Stand, Fehlermo¨ Glichkeiten Und Verbesserungsvorschla¨Ge

    Drug Screening: Actual Status, Pitfalls and Suggestions for Improvement Drogenscreening: Gegenwa¨ Rtiger Stand, Fehlermo¨ Glichkeiten Und Verbesserungsvorschla¨Ge

    J Lab Med 2004;28(4):317–325 ᮊ 2004 by Walter de Gruyter • Berlin • New York 2004/03304 Drug Monitoring und Toxikologie Redaktion: V. W. Armstrong Drug screening: Actual status, pitfalls and suggestions for improvement Drogenscreening: Gegenwa¨ rtiger Stand, Fehlermo¨ glichkeiten und Verbesserungsvorschla¨ge Wolf R. Ku¨ lpmann* pretierbar. In Wirklichkeit mu¨ ssen viele Aspekte beru¨ ck- sichtigt werden, um einen aussagekra¨ ftigen Befund zu Klinische Chemie, Medizinische Hochschule Hannover, erhalten, z.B. Pra¨ analytik, Spezifita¨ t und Empfindlichkeit Hannover, Germany des Verfahrens oder Qualita¨ tssicherung. Obwohl die Abstract mechanisierten Meßverfahren naturgema¨ ß quantitative Ergebnisse liefern, wird aufgezeigt, daß es sich in der Immunoassays for drug screening are often regarded as Regel empfiehlt, qualitative Befunde zu erstellen. Die procedures which are easily performed and interpreted. Verfahren erlauben aber im Gegensatz zu den auch fu¨r But in fact, many aspects have to be considered to diese Zwecke verwendeten Teststreifen die Entschei- obtain a meaningful result. Among these are sampling, dungsgrenze (cut-off) der jeweiligen Fragestellung anzu- specificity and sensitivity of assays, and quality assess- passen, z.B. bei akuter Intoxikation, chronischem Abusus ment. Although the mechanised procedures yield quan- oder U¨ berwachung des Drogenentzugs. titative results, there are good reasons to generally report Ein schwerwiegender Nachteil von Immunoassays zum qualitative findings. The mechanised procedures allow Nachweis von Amphetamin und a¨ hnlichen Substanzen, the adjustment of the cut-off concentration to the clinical Barbituraten, Benzodiazepinen und Opiaten besteht dar- setting, e.g. in the case of acute intoxication, chronic in, daß eine starke Kreuzreaktivita¨ t des Antiko¨ rpers abuse or drug withdrawal, an important advantage as gegenu¨ ber pharmakologisch wenig wirksamen Verbin- compared to test strips.
  • Antipsychotics

    Antipsychotics

    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluations: Antipsychotics Date of Review: May 2016 End Date of Literature Search: February 2016 New Drugs: brexpiprazole Brand Names (Manufacturer): Rexulti® (Otsuka) cariprazine Vraylar™ (Actavis) Dossiers Received: yes PDL Classes: Antipsychotics, First generation Antipsychotics, Second generation Antipsychotics, Parenteral Current Status of PDL Class: See Appendix 1. Purpose for Class Update: Several new antipsychotic drug products have been approved by the U.S. Food and Drug Administration since these drug classes were last reviewed by the Oregon Health Plan (OHP) Pharmacy and Therapeutics Committee. Research Questions: 1. Is there new comparative evidence of meaningful difference in efficacy or effectiveness outcomes for schizophrenia, bipolar mania or major depressive disorders (MDD) between oral antipsychotic agents (first‐ or second‐generation) or between parenteral antipsychotic agents (first‐ or second‐generation)? 2. Is there new comparative evidence of meaningful difference in harms between oral antipsychotic agents (first‐ or second‐generation) or between parenteral antipsychotic agents (first‐ or second‐generation)? 3. Is there new comparative evidence of meaningful difference in effectiveness or harms in certain subpopulations based on demographic characteristics? Conclusions: There is insufficient evidence of clinically meaningful differences between antipsychotic agents in efficacy or effectiveness or harms between antipsychotic agents for schizophrenia, bipolar mania or MDD. There is insufficient evidence to determine if brexpiprazole and cariprazine offer superior efficacy or safety to other antipsychotic agents for schizophrenia. There is insufficient evidence to determine if brexpiprazole offers superior efficacy or safety to other antipsychotic agents for MDD.
  • Clopixol Acuphase®)

    Clopixol Acuphase®)

    Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Version 3.1 – January 2018 GUIDELINE REPLACED Version 3 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED October 2015 NEXT REVIEW DATE January 2021 EXECUTIVE SPONSOR Executive Medical Director ORIGINAL AUTHOR Jed Hewitt – Chief Pharmacist Review / update – 2015 Helen Manuell – Lead Pharmacist (ESx) Review / update - 2018 Jed Hewitt – Chief Pharmacist If you require this document in an alternative format, i.e. easy read, large text, audio or Braille please contact the pharmacy team on 01243 623349. Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Introduction In the past, Acuphase® has often been too widely and possibly inappropriately used, sometimes without full regard being given to the fact that it is a potentially hazardous and toxic preparation with very little published information to support its use. Indeed, the Cochrane Library concludes that there is inadequate data on Acuphase® and no convincing evidence to support its use in acute psychiatric emergency. So far as possible, it should therefore be reserved for the minority of patients who have a prior history of previous use and good response, with use defined in an advance directive. Similarly, as a general rule Acuphase® should not be used for rapid tranquillisation unless such practice is also in accordance with an advance directive. Normally, Acuphase® should never be considered as a first-line drug for rapid tranquillisation as its onset of action will often not be rapid enough in these circumstances. In addition, the administration of an oil-based injection carries very high risk in a highly agitated patient.
  • Screening of 300 Drugs in Blood Utilizing Second Generation

    Screening of 300 Drugs in Blood Utilizing Second Generation

    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
  • Emea/666243/2009

    Emea/666243/2009

    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
  • Pharmacokinetic Considerations in Antipsychotic Augmentation Strategies: How to Combine Risperidone with Low-Potency Antipsychotics

    Pharmacokinetic Considerations in Antipsychotic Augmentation Strategies: How to Combine Risperidone with Low-Potency Antipsychotics

    Progress in Neuro-Psychopharmacology & Biological Psychiatry 76 (2017) 101–106 Contents lists available at ScienceDirect Progress in Neuro-Psychopharmacology & Biological Psychiatry journal homepage: www.elsevier.com/locate/pnp Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics Michael Paulzen a,b,1, Georgios Schoretsanitis a,b,f,⁎,1, Benedikt Stegmann d,ChristophHiemkeg,h, Gerhard Gründer a,b,KoenR.J.Schruerse, Sebastian Walther f, Sarah E. Lammertz a,b,EkkehardHaenc,d a Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany b JARA – Translational Brain Medicine, Aachen, Germany c Clinical Pharmacology, Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany d Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany e Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands f University Hospital of Psychiatry, Bern, Switzerland g Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany h Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Germany article info abstract Article history: Objectives: To investigate in vivo the effect of low-potency antipsychotics on metabolism of risperidone (RIS). Received 22 December 2016 Methods: A therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-OH- Accepted 12 March 2017 RIS of 1584 patients was analyzed. Five groups were compared; a risperidone group (n = 842) and four co- med- Available online 14 March 2017 ication groups; a group co-medicated with chlorprothixene (n = 67), a group with levomepromazine (n = 32), a group with melperone (n = 46), a group with pipamperone (n = 63) and a group with prothipendyl (n = 24).
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine